The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, ...

Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a ...

Francis is enthusiastic about Teva's branded drugs, and presented the developments of prominent products. On Austedo ( for ...

Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

According to statements made by the CEO at Teva and a top executive at Novo Nordisk, both manufacturers had considered the possibility that their popular drugs, Austedo and Ozempic, respectively ...

Teva Pharmaceuticals Inc. is doubling down on its fight against ... challenging how the Centers for Medicare & Medicaid Services picked its drugs used to treat movement disorders—Austedo and Austedo ...

Also underway, on the flipside, was the decision to ramp up investment in one of Teva’s stable of innovative products, Austedo (deutetrabenazine), a treatment for tardive dyskinesia and chorea ...

Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar ...